The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...

Patients should never be treated as passive recipients of AI-enabled outputs. The enduring principles of patient-centred research show that it is precisely the active engagement of patients in the ...

Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...

There’s a clear gap: output is rising, but engagement isn’t. This often happens because many strategies focus on HCPs’ ...

Medical Affairs is operating at a pivotal moment. Expectations have expanded rapidly – deeper scientific exchange, sharper ...

Johnson & Johnson (J&J) has announced US FDA approval for Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat adults with relapsed or refractory multiple ...

Johnson & Johnson’s (J&J) nipocalimab, a potential immunoselective investigational treatment for adults with systemic lupus ...

The elected employee representatives will join the Board of Directors after the annual general meeting on 26 March 2026 ...

UK biotech N4 Pharma, a company developing a gene delivery system to enable advanced therapies for cancer and other diseases, ...

Despite the GenAI fervour, there is an acute need to prepare organisations to understand which specific tools they need and ...

Stop pushing content at a burnt-out audience and start creating "Digital Magnetism." Join Impetus Digital to unlock the 2026 ...

Building on proven methodology, STEM AI was developed to provide an even deeper level of insight for organisations looking to use generative AI to further accelerate team performance. Drawing on ...